With a global reach, Hogan Lovells International LLP is equipped to handle a full scope of life sciences matters from clinical trials, business development and IP to corporate and commercial transactions, complex litigation and investigations. The team is jointly led by Lu Zhou, an expert in complex cross-border transactions, licensing deals and joint ventures, and Calvin Ding, who has over a decade of experience advising on litigation, regulatory, compliance, and government investigation matters. Roy Zou is well-versed in commercial transactions and financial due diligence reviews of Chinese companies for multinational corporations and investors, while dually qualified PRC and U.S lawyer Katie Feng excels across the full spectrum of IP, particularly litigation. Jessie Xie assists clients in the pharmaceutical, medical device, and healthcare sectors with commercial contracts, strategic operations, and regulatory matters.
Legal 500 Editorial commentary
Accolades
Client satisfaction
Testimonials
Collated independently by Legal 500 research team.
‘Calvin Ding is a true leader in the space who is totally dedicated to his clients. He has in-depth knowledge of the pharmaceutical industry and intimately understands the challenges pharmaceutical companies encounter in the highly volatile Asia region. He is constantly staying on top of developments in the market and industry and making sure all of his clients are informed. ’
‘Calvin Ding doesn't just focus on the industry, but he really drills down into my business and the unique challenges we are facing as an individual company. He always takes time to meet with his client and makes himself available 24/7.’
Key clients
- Merck
- Medera Inc.
- Sinopharm Commonwealth Company Limited
Work highlights
Advising Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company, on its proposed debut on the Nasdaq through a de-SPAC merger with Keen Vision Acquisition Corporation (NASDAQ: KVAC) (“Keen Vision”) with a US$622.6 million pre-merger valuation.
Advised pharmaceutical company Merck (NYSE: MRK), known as MSD outside of the United States and Canada, in connection with its transaction with Curon Biopharmaceutical Limited (Curon), a privately held biotechnology company, under which Merck, through a subsidiary, has acquired CN201.
Advising Merck & Co., Inc. and Merck Sharp & Dohme LLC in connection with a major cross-border litigation concerning rights in the MERCK trademark and trade name.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Practice head
Lu Zhou; Calvin Ding
Other key lawyers
Roy Zou; Katie Feng; Jessie Xie